Identification of CD66c as a potential target in gastroesophageal junction cancer for antibody–drug conjugate development
This preclinical study provides a strong rationale for the further development of CD66c-DXd as promising therapeutic candidates to treat advanced GEJ cancer. Additionally, the study demonstrates the robustness of the multi-omics data in identifying novel potential ADC targets and payloads.
Authors
- Shili Yao
- Changjuan Tao (ORCID: https://orcid.org/0000-0002-8987-4542)
- Yun Xi (ORCID: https://orcid.org/0000-0002-7757-9650)
- Yang Liu (ORCID: https://orcid.org/0000-0002-9442-700X)
- Peng Zhang (ORCID: https://orcid.org/0000-0002-4465-5143)
- Ye Lu (ORCID: https://orcid.org/0000-0002-4967-5557)
- Yuan Li (ORCID: https://orcid.org/0000-0002-6245-9437)
- Xiangdong Cheng (ORCID: https://orcid.org/0000-0003-1470-2831)
- Peng Guo (ORCID: https://orcid.org/0009-0001-4332-2486)
- Hanfei Xie
Institutions
- Tianjin University (CN)
- Chinese Academy of Sciences (CN)
- Wenzhou Medical University (CN)
- Zhejiang Cancer Hospital (CN)
- Zhejiang Provincial People's Hospital (CN)
Publication Details
- Journal
- Gastric Cancer
- Published
- 2025-02-07
- DOI
- https://doi.org/10.1007/s10120-025-01584-z
- Citations
- 2
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Innovative Research Group Project of the National Natural Science Foundation of China
- National Natural Science Foundation of China
- Key Technologies Research and Development Program
- National Key Research and Development Program of China
- Medical Science and Technology Project of Zhejiang Province
- Natural Science Foundation of Zhejiang Province
- Science and Technology Program of Zhejiang Province